Understanding the scientific issues embedded in the generic drug approval process.

Area of Science:

• Pharmacology and Pharmaceutical Sciences
• Regulatory Science

Background:

• The generic drug approval process relies on establishing bioequivalence between generic and brand-name medications.
• Despite established regulations for over two decades, scientific controversies regarding bioequivalence persist.

Purpose of the Study:

• To critically review the key scientific challenges within the generic drug approval pathway.
• To assess the current state of understanding and consensus on bioequivalence issues among stakeholders.

Main Methods:

• Comprehensive literature search using terms like 'generic drugs' and 'bioequivalence' across major scientific databases (MEDLINE, IPA, CINAHL, SCI).
• Inclusion of regulatory documents, including the Code of Federal Regulations and Food and Drug Administration (FDA) guidances.

Main Results:

• Ongoing scientific discussions and evolving FDA guidances highlight persistent bioequivalence controversies.
• A significant gap exists in clinician and consumer understanding of the scientific basis for generic drug approval and bioequivalence.
• The current generic drug approval framework is considered functional despite identified challenges.

Conclusions:

• A thorough understanding of the generic drug approval process and bioequivalence principles is crucial for healthcare professionals and researchers.
• Addressing knowledge gaps can enhance trust and informed decision-making regarding generic medications.